CAR T-cell therapy is a type of cancer treatment where a patient's own T-cells (a type of immune cell in the blood) are genetically engineered in a lab to recognize and kill cancer cells.  Car-T cell therapy today is a very manual and labor intensive process, prone to error and contamination risk at every step. By automating it with robotic equipment, we're able to reduce this contamination risk and also hopefully increase access to additional patients and reduce costs. Exciting next moves to come as we continue to announce more progress and advancements!

Today, we have built a system with 4 robotic arms, 2 on the ceiling, and 2 with additional axis on a gantry system. We use custom in house designed end effectors, modules for each piece of equipment, and our own fluid transfer and connection intellectual property. The company has partnered with several large pharmaceutical companies with already FDA approved therapies, as well as more still in development.

We collaborate closely with big players in the robotics and medical device space, from Universal Robots to Thermofisher. 

Universal Robots: Press 

Thermofisher Press

Our hardware team comes from an extensive group of universities and industry leaders. Today, I am in charge of leading and delivering our hardware solution, both mechanical design, safety, and electromechanical sub systems. 

Read more about my specific team here

While the system is inherently sterile and safe inside of the robotic cell, the system still requires consumables and preparing parts for the rest of the robotic interactions. We're currently exploring our options as the humanoid and Gen AI wave is increasing the availability of hardware and tooling for making these practically deployable. 

Read more from Multiply Labs directly if you'd like to learn more!